Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18921517 | 1.00 | SLC18A3 (0.39) | SLC18A3SIGMAR1MEN1KMT2APRCP | |
| SCHEMBL22232773 | 1.00 | SLC18A3 (0.39) | SLC18A3SIGMAR1MEN1KMT2APRCP | |
| SCHEMBL31087320 | 0.88 | NLRP3 (0.37) | SLC18A3SIGMAR1MEN1KMT2APRCP | |
| SCHEMBL24726482 | 0.84 | SLC5A2 (0.37) | SLC18A3SIGMAR1MEN1KMT2AHTR2B | |
| SCHEMBL29729987 | 0.84 | SLC5A2 (0.37) | SLC18A3SIGMAR1MEN1KMT2AHTR2B | |
| SCHEMBL30678295 | 0.84 | SLC5A2 (0.37) | SLC18A3SIGMAR1MEN1KMT2AHTR2B | |
| SCHEMBL30678290 | 0.80 | KCNH2 (0.51) | MEN1KMT2ATSHRNPC1 | |
| SCHEMBL29729997 | 0.80 | KCNH2 (0.51) | MEN1KMT2ATSHRNPC1 | |
| SCHEMBL30064507 | 0.80 | KCNH2 (0.51) | MEN1KMT2ATSHRNPC1 | |
| SCHEMBL30678293 | 0.80 | GRM5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI, INC. (KR) | 2025-12-04 | — | — | US | claimed |
| WO-2022245085-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | 보로노이바이오 주식회사 | 2022-11-24 | — | — | WO | claimed |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-27 | — | — | US | disclosed |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | VORONOI INC. (KR) | 2026-01-20 | — | — | US | disclosed |
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | VORONOI, INC. (KR) | 2025-12-04 | — | — | US | disclosed |
| EP-4430037-B1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-10-29 | — | — | EP | disclosed |
| EP-4631507-A2 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | Voronoi Inc. (KR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619403-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | Voronoi, Inc. (KR) | 2025-09-24 | — | — | EP | disclosed |
| EP-3943491-B1 | HETEROARYL DERIVATIVE, METHOD FOR PRODUCING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE COMPONENT | VORONOI INC (KR) | 2025-06-18 | — | — | EP | disclosed |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | GENZYME CORP (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | VORONOI INC. (KR) | 2025-01-16 | — | — | US | disclosed |
| US-20040018724-A1 | Plating method | SHIPLEY COMPANY, L.L.C (US) | 2004-01-29 | — | — | US | disclosed |
| EP-1353228-A1 | Method for depositing a very thick photoresist layer on a substrate and metal plating method | Shipley Co. L.L.C. (US) | 2003-10-15 | — | — | EP | disclosed |
| US-5900346-A | NEGATIVE-ACTING PHOTORESIST COMPOSITION; PHOTOACTIVATOR THAT IS AN ORGANIC CARBONYL CONTAINING COMPOUND; CROSSLINKER. | SHIPLEY COMPANY, L.L.C. (US) | 1999-05-04 | — | — | US | disclosed |
| US-5478690-A | Alkali developable photosensitive resin composition comprising a binder having betaine side groups | NIPPON PAINT CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0499447-A1 | Alkali developable photosensitive resin composition | Nippon Paint Co., Ltd. (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0490118-A1 | Photoimagable solder mask and photosensitive composition | SHIPLEY COMPANY INC. (US) | 1992-06-17 | — | — | EP | disclosed |
| US-4877818-A | PHOTORESISTS | ROHM AND HAAS COMPANY (US) | 1989-10-31 | — | — | US | disclosed |
| US-4592816-A | Forming negative images on conductive surfaces | ROHM AND HAAS COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0176356-A2 | Photosensitive polymer compositions, electrophoretic deposition processes using same, and the use of same in forming films on substrates | ROHM AND HAAS COMPANY (US) | 1986-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368635-A1 | HETEROARYL DERIVATIVE COMPOUND, AND USES THEREOF | ERBB2, EGFR, ERBB3 | SLC18A3 4510/4885SIGMAR1 2989/4885MEN1 3930/4885 |
| US-20250122186-A1 | ISOXAZOLIDINES AS RIPK1 INHIBITORS AND USE THEREOF | RIPK1, RIPK2, RIPK3 | SLC18A3 4567/4885SIGMAR1 2075/4885MEN1 4437/4885 |
| US-12528799-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | SLC18A3 4538/4885SIGMAR1 166/4885MEN1 3907/4885 |
| US-12534457-B2 | Heteroaryl derivative compounds, and uses thereof | ERBB2, EGFR, ERBB3 | SLC18A3 4367/4885SIGMAR1 287/4885MEN1 2781/4885 |
| US-20250019373-A1 | ARYL OR HETEROARYL DERIVATIVE, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME AS ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF KINASE-RELATED DISEASES | RIPK1, RIPK2, RIPK3 | SLC18A3 4854/4885SIGMAR1 3575/4885MEN1 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.